Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?
Immunohorizons
; 5(7): 535-542, 2021 07 14.
Article
em En
| MEDLINE
| ID: mdl-34261674
ABSTRACT
In 1986, The New England Journal of Medicine published George Eisenbarth's (Eisenbarth. 1986. N. Engl. J. Med. 314 1360-1368) model of type 1 diabetes (T1D) as a chronic autoimmune disease. In 2019, the same journal published the results of the teplizumab trial, which showed the anti-CD3 mAb delayed T1D progression in high-risk individuals. Although teplizumab is the first immunomodulatory agent to demonstrate significant delay in disease progression, it is also one of the few tested prior to clinical disease onset. Is it possible, then, that this trial's success is as much about the agent as it is about its timing? This commentary will review the landscape of immune intervention in T1D since 1986, discuss the teplizumab trial results, and finally, speculate on whether current paradigms for T1D immune intervention should focus less on disease development as a continuum and more on the stages of T1D progression as distinct disease processes.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 1
/
Tempo para o Tratamento
/
Agentes de Imunomodulação
/
Imunoterapia
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article